Special Issue

The Impact of Mass Spectrometry-Based Omics Approaches in the Fight against COVID-19: From the Diagnosis to Therapies

Message from the Guest Editor

There is an urgent need to better understand the molecular mechanisms involved in the SARS-CoV-2 life cycle and in its variants in order to fight the pandemic with appropriate diagnostic and therapeutic interventions. Mass-spectrometry-based proteomics has addressed and could further impressively address important issues including how to increase testing capacity, how the virus causes disease, which key regulators are implicated in the host response, what the cellular and systemic processes or pathways involved in the human immune system are, and many others. In the actual efforts to overcome COVID-19, however, additional studies are mandatory. This Special Issue will include articles and reviews that contribute through the means of proteomics and other integrated omics approaches to answer the various research questions around this pandemic.

Guest Editor

Prof. Dr. Rosa Terracciano

Department of Experimental and Clinical Medicine, Laboratory of Mass Spectrometry and Proteomics, University "Magna Græcia", Catanzaro, Italy

Deadline for manuscript submissions

closed (31 May 2022)



an Open Access Journal by MDPI

Indexed in Scopus



mdpi.com/si/88476

BioChem Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biochem@mdpi.com

mdpi.com/journal/biochem





an Open Access Journal by MDPI

Indexed in Scopus



About the Journal

Message from the Editor-in-Chief

BioChem is an international and interdisciplinary open access journal encompassing the fields of molecular biology, cell biology, structural biology, nucleic acid biology, chemical biology, synthetic biology, disease biology, biophysics, and theoretical biochemistry. It publishes reviews, research articles, communications, and letters. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible.

Editor-in-Chief

Prof. Dr. Buyong Ma

School of Pharmacy, Shanghai Jiaotong University, Shanghai, China

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, EBSCO and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 33.9 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

